在现实生活中Tralokinumab的有效性和安全性:可能的预测性快速反应因素
Luca Potestio1, Cataldo Patruno2, Maddalena Napolitano1
1From the Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.
Dermatitis : contact, atopic, occupational, drug
|November 14, 2023
概括
特拉洛金马布有效地治疗中度至重度的亚托皮性皮肤炎 (AD). 诸如较高的和复发性疾病等因素预测治疗反应的更快开始,没有观察到显著的不良事件.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 亚托皮炎 (AD) 是一种慢性炎症性皮肤疾病.
- 特拉洛基努马布是最近批准用于中度至重度AD的生物药物.
- 在阿尔茨海默病中,对特拉洛金努马布反应的预测因素尚未得到充分确立.
研究的目的:
- 评估特拉洛金纽马布在阿兹海默症患者中的实际有效性和安全性.
- 确定预测治疗响应开始时间的因素.
主要方法:
- 一个单一中心的回顾性研究,对57名阿尔茨海默症患者进行了治疗,他们接受了tralokinumab治疗长达24周以上.
- 在基线时评估AD严重程度 (EASI,IGA) 和 (NRS),W16和W24.
- 评估与治疗相关的不良事件 (AE).
主要成果:
- 特拉洛基努马布从W4到W24显示了AD严重程度的持续改善.
- 较高的基线 (NRS ≥8),复发性AD,较低的EASI (≤24) 和较低的IGA (≤3) 预测了W16更快的EASI75反应.
- 性别,年龄,阿托皮性并发症和先前的治疗没有影响结果.
- 没有报告任何重大不良事件.
结论:
- 特拉洛基努马布在中度至重度的亚托皮性皮炎中是有效和安全的.
- 快速反应的预测因素包括较高的,复发性疾病过程和较低的基线疾病严重程度.
- 这些发现有助于优化特拉洛基努马布治疗策略.
更多相关视频
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
636
相关概念视频
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).